Advertisement
Loading...

Autolus Therapeutics plc

AUTL•NASDAQ
Healthcare
Biotechnology
$1.59
$-0.12(-7.02%)
U.S. Market opens in NaNh NaNm

Autolus Therapeutics plc (AUTL) Stock Overview

Explore Autolus Therapeutics plc’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

Z

Key Financials

Market Cap423.2M
P/E Ratio-1.47
EPS (TTM)$-1.08
ROE-0.99%
Fundamental Analysis

AI Price Forecasts

1 Month$1.28
3 Months$1.39
1 Year Target$0.00

AUTL Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Autolus Therapeutics plc (AUTL) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

The current technical analysis reveals key indicators including an RSI of 53.06, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $0.00.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -1.47 and a market capitalization of 423.2M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

1-Day Change
-7.02%
5-Day Change
-1.85%
1-Month Change
7.43%
3-Month Change
13.57%
6-Month Change
16.06%
Year-to-Date (YTD) Change
-20.10%
1-Year Change
30.33%
3-Year Change
-36.90%
5-Year Change
-74.23%
All-Time (Max) Change
-93.64%

Contact Information

https://www.autolus.com
44 20 3829 6230
The MediaWorks, London, NaN, W12 7FP

Company Facts

647 Employees
IPO DateJun 22, 2018
CountryGB
Actively Trading

Frequently Asked Questions